Opko Health Inc. (NYSE: OPK) is buying Israeli biopharmaceutical company Prolor Biotech Inc. (NYSE: PBTH) in an all-stock deal valued at $480 million.

Prolor aims to develop alternative-acting versions of already approved medications, including human growth hormone and clotting therapies for hemophilia.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.